Cholestasis Clinical Trial
OBJECTIVES: I. Compare conjugated bilirubin levels and serum bile acid levels in severely
premature newborns on long term parenteral nutrition and given either sincalide or placebo.
II. Compare morbidity and mortality rates in this patient population. III. Evaluate
ultrasonographic images of the hepatobiliary tree during and 1 to 2 years after the
administration of sincalide or placebo to assess the development of biliary sludge and
biliary stone formation.
PROTOCOL OUTLINE: This is a randomized, placebo controlled, double blind, multicenter study.
Patients are stratified according to prematurity or surgical group.
Patients are randomized to receive either placebo or sincalide IV over 10 to 15 minutes
every 12 hours until a total of 8 weeks of therapy is administered or greater than 50% of
their nutrition is enteral.
Patients are followed for a maximum of 2 years.
Completion date provided represents the completion date of the grant per OOPD records
;
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Completed |
NCT00738101 -
Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
|
N/A | |
Completed |
NCT03662282 -
Omegaven as Alternative Parenteral Fat Nutrition
|
Phase 3 | |
Recruiting |
NCT02334293 -
Omegaven® as Parenteral Nutrition
|
N/A | |
Recruiting |
NCT01252043 -
Retrospective Review of CT and MR in Pediatric Patients With Cholestasis
|
N/A | |
Completed |
NCT00846963 -
Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00007033 -
Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
|
N/A | |
Completed |
NCT01194063 -
Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children
|
Phase 3 | |
Recruiting |
NCT01998620 -
Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis
|
Phase 4 | |
Completed |
NCT00080236 -
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
|
Phase 2 | |
Completed |
NCT00058890 -
Gabapentin to Treat Itch in Patients With Liver Disease
|
Phase 3 | |
Active, not recruiting |
NCT00004315 -
Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease
|
Phase 2 | |
Active, not recruiting |
NCT02922751 -
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
|
||
Completed |
NCT04604652 -
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
|
Phase 2 | |
Terminated |
NCT02267707 -
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
|
Phase 1 | |
Completed |
NCT02357576 -
Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD
|
Phase 3 | |
Completed |
NCT02721277 -
SMOFlipid to Lessen the Severity of Neonatal Cholestasis
|
Phase 1/Phase 2 | |
Terminated |
NCT02767648 -
Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region
|
N/A | |
Completed |
NCT01073202 -
Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation
|
N/A |